Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Recruiting Observational

Evaluation of the Clinical Outcomes of the Total Knee ps Prosthesis Implanted With the Use of Inertial Sensors

NCT06321042 · tracked via the Priya Life Science Italy tracker
Phase
Observational
Started
2023-01-13
Last updated
2026-04-23

Condition(s) studied

Prosthesis Durability

Investigational drug(s) / intervention(s)

Knee arthroplasty

Knee arthroplasty: Knee arthroplasty surgery with perseus orthokey alignment device

Study summary

evaluate the clinical outcome of the implantation of a specific primary TKA model implanted with the aid of inertial sensors for the execution of bone cuts through the administration of questionnaires for the calculation of clinical-functional scores;

Eligibility

Sex
ALL
Min age
50 Years
Max age
85 Years
Healthy volunteers
No
Inclusion Criteria: 1. Male and female subjects 50 years of age or older and less than 85 years of age (\>50 and \<85 years) who are candidates for primary cemented total knee replacement based on physical examination and medical history, including diagnosis of severe knee pain and disability due to at least one of the following causes: * to. Primary or secondary osteoarthritis * b. Collagen disorders and/or avascular necrosis of femoral condyle * c. Moderate valgus, varus or flexion deformities (HKA between ± 10°, flexion contracture \<10°) - 2. Patients consent and able to complete scheduled study procedures and follow-up assessments. 3. Patients informed about the nature of the study who signed the "informed consent" approved by the ethics committee. Exclusion Criteria: * Simultaneous participation in other studies * Patients not capable of understanding and wanting and therefore unable to sign the informed consent * Patients who have already undergone hip or ankle arthroplasty, previous osteotomy, with severe axial deformities or suffering from rheumatoid arthritis, diabetes or neuromuscular diseases.

Primary outcome measure(s)

  • Knee Society Score — at baseline (day 0)
    Two sections, one evaluating the patient's function and one for his clinical conditions, overall score goes from 0 to 100
  • Knee Society Score — 6 months
    Two sections, one evaluating the patient's function and one for his clinical conditions, overall score goes from 0 to 100
  • Knee Society Score — 12 months
    Two sections, one evaluating the patient's function and one for his clinical conditions, overall score goes from 0 to 100
  • Knee Society Score — 24 months
    Two sections, one evaluating the patient's function and one for his clinical conditions, overall score goes from 0 to 100
  • Western Ontario and McMaster Universities Arthritis Index — at baseline (day 0)
    The test evaluates main aspects of arthritis such as pain, stiffness articulation and functionality. The score goes from 0 to 96
  • Western Ontario and McMaster Universities Arthritis Index — 6 months
    The test evaluates main aspects of arthritis such as pain, stiffness articulation and functionality. The score goes from 0 to 96
  • Western Ontario and McMaster Universities Arthritis Index — 12 months
    The test evaluates main aspects of arthritis such as pain, stiffness articulation and functionality. The score goes from 0 to 96
  • Western Ontario and McMaster Universities Arthritis Index — 24 months
    The test evaluates main aspects of arthritis such as pain, stiffness articulation and functionality. The score goes from 0 to 96
  • Knee injury and Osteoarthritis Outcome Score — at baseline (day 0)
    The KOOS holds five separately scored subscales: Pain, other Symptoms, Function in daily living (ADL), Function in Sport and Recreation (Sport/Rec), and knee-related Quality of Life (QOL). the score goes from 0 to 100
  • Knee injury and Osteoarthritis Outcome Score — 6 months
    The KOOS holds five separately scored subscales: Pain, other Symptoms, Function in daily living (ADL), Function in Sport and Recreation (Sport/Rec), and knee-related Quality of Life (QOL). the score goes from 0 to 100
  • Knee injury and Osteoarthritis Outcome Score — 12 months
    The KOOS holds five separately scored subscales: Pain, other Symptoms, Function in daily living (ADL), Function in Sport and Recreation (Sport/Rec), and knee-related Quality of Life (QOL). the score goes from 0 to 100
  • Knee injury and Osteoarthritis Outcome Score — 24 months
    The KOOS holds five separately scored subscales: Pain, other Symptoms, Function in daily living (ADL), Function in Sport and Recreation (Sport/Rec), and knee-related Quality of Life (QOL). the score goes from 0 to 100
  • 36-Item Short Form Health Survey — at baseline (day 0)
    is a valid and reliable tool for measuring health outcomes in patients with musculoskeletal pain, but its sensitivity to clinical changes in patients with specific disorders may be limited, rated on a scale of 0 to 100, with 0 and 100 being minimum and maximum possible scores.
  • 36-Item Short Form Health Survey — 6 months
    is a valid and reliable tool for measuring health outcomes in patients with musculoskeletal pain, but its sensitivity to clinical changes in patients with specific disorders may be limited, rated on a scale of 0 to 100, with 0 and 100 being minimum and maximum possible scores.
  • 36-Item Short Form Health Survey — 12 months
    is a valid and reliable tool for measuring health outcomes in patients with musculoskeletal pain, but its sensitivity to clinical changes in patients with specific disorders may be limited, rated on a scale of 0 to 100, with 0 and 100 being minimum and maximum possible scores.
  • 36-Item Short Form Health Survey — 24 months
    is a valid and reliable tool for measuring health outcomes in patients with musculoskeletal pain, but its sensitivity to clinical changes in patients with specific disorders may be limited, rated on a scale of 0 to 100, with 0 and 100 being minimum and maximum possible scores.
  • Forgotten joint score — at baseline (day 0)
    a 12-question patient-reported outcomes measure created to measure a patient's awareness of their artificial joint
  • Forgotten joint score — 6 months
    a 12-question patient-reported outcomes measure created to measure a patient's awareness of their artificial joint
  • Forgotten joint score — 12 months
    a 12-question patient-reported outcomes measure created to measure a patient's awareness of their artificial joint
  • Forgotten joint score — 24 months
    a 12-question patient-reported outcomes measure created to measure a patient's awareness of their artificial joint

Trial sites (1)

FacilityCityRegionStatus
Stefano Zaffagnini Bologna Italia Recruiting

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06321042 on ClinicalTrials.gov ↗ ← All trials in Italy